Lobbying efforts have ensured that long-term care residents and other seniors are commonly prescribed the expensive drug Lucentis, even though the less costly drug Avastin has proven equally effective, suggests a USA TODAY article published Thursday. Lucentis in fact has become the No. 1 drug reimbursed by Medicare.
Alzheimer's researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.
The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.
In order to promote coordination between Medicare and Medicaid services and to save money, the federal government and states should create an integrated care model for dual-eligible beneficiaries, a new report recommends.
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.
Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.